Profusa to Present US-Study Clinical Data at Leipzig Interventional Course (LINC) 2026

Rhea-AI Summary

Profusa (Nasdaq: PFSA) announced that an abstract from its US pilot clinical study of the Lumee tissue oxygen monitoring technology in peripheral artery disease (PAD) patients was accepted for presentation at Leipzig Interventional Course (LINC) 2026.

The presentation is scheduled for January 28, 2026 at 9:45am CET in Trade Fair Leipzig, Hall 2, and will share additional clinical insights comparing Lumee tissue oxygen monitoring with tcpO2 from US sites. The company describes Lumee as a continuous, real-time implantable oxygen sensor intended for clinic and at-home use. Management highlighted positive feedback from the US study and plans to discuss results with providers and researchers at the conference.

Key Figures

LINC 2026 dates January 27–30, 2026 Leipzig Interventional Course (LINC) 2026 conference window

Presentation time 9:45 am CET, Jan 28, 2026 Scheduled Lumee PAD clinical data presentation at Trade Fair Leipzig, Hall 2

Market Reality Check

$0.1525 Last Close

Volume Volume 5,937,805 is below 20-day average of 8,881,027 (relative volume 0.67). low

Technical Price at 0.175 is trading below the 200-day MA of 0.42 and far under the 2.40 52-week high.

Peers on Argus

Peers in Medical Devices show small mixed moves (e.g., AIMD -2.26%, ALUR -2.94%, others flat), suggesting PFSA’s -5.2% move is more stock-specific than broad sector-driven.

Historical Context

Date	Event	Sentiment	Move	Catalyst
Nov 24	Clinical data update	Positive	+8.4%	Acceptance of late-breaking U.S. Lumee clinical trial update in Paris.
Nov 19	Earnings & financing	Positive	-6.0%	Q3 2025 highlights with reduced net debt and outlined revenue potential.
Oct 30	Commercial roadmap	Positive	-9.8%	Detailed Lumee commercialization plan and long-term revenue targets.
Oct 28	Manufacturing milestone	Positive	-2.1%	Completion of manufacturing build-out to support early 2026 shipments.
Oct 22	Distribution expansion	Positive	-8.1%	New European distributor expanding Lumee Oxygen market coverage.

Pattern Detected

Recent positive operational and commercial updates have often coincided with negative 24h price reactions, except for the prior clinical-trial conference update, which saw gains.

Recent Company History

Over the last few months, Profusa has focused on advancing and commercializing its Lumee tissue oxygen platform. On Oct 22 and Oct 28, it expanded European distribution and completed manufacturing build-out ahead of early 2026 shipments. Subsequent filings detailed PIPE financings and SPAC-related structures. On Nov 24, the company highlighted U.S.-based clinical trial data at Paris Vascular Insights, which drew a positive 8.38% move. Today’s LINC 2026 presentation acceptance continues this stream of clinical visibility around Lumee in PAD.

Market Pulse Summary

This announcement highlights acceptance of Profusa’s U.S.-based pilot clinical data on Lumee tissue oxygen monitoring in PAD patients for presentation at LINC 2026, building on the prior Paris Vascular Insights update. Recent news flow has emphasized European distribution expansion, completion of manufacturing build-out, and detailed commercialization timelines into 2026 and beyond. Regulatory filings also describe structured PIPE financings and going-concern language. Investors may watch forthcoming clinical details, execution on early revenue, and any additional capital-raising disclosures as key markers.

Key Terms

peripheral artery disease medical

"evaluates LumeeTM in peripheral artery disease (PAD) patients"

A circulatory condition in which arteries that supply blood to the legs and feet become narrowed or blocked, reducing blood flow and causing pain, slow healing, or tissue damage—think of it as clogged pipes in the body’s lower limbs. It matters to investors because the prevalence, available treatments, and clinical trial or regulatory outcomes shape demand for drugs, devices, and care services, which can affect revenues, costs and valuation in healthcare-related businesses.

tissue oxygen monitoring medical

"additional insights into tissue oxygen monitoring of PAD patients"

Tissue oxygen monitoring is a medical technology that measures how much oxygen is reaching body tissues, using sensors placed on or in the body to track local oxygen levels over time. Investors care because these measurements can signal patient stability, guide treatment decisions, and reduce complications, making the devices and related services potentially valuable if they win clinical acceptance, regulatory approval, and insurance reimbursement — similar to how a moisture meter helps a gardener keep plants healthy.

tcpO2 medical

"evaluating our pioneering Lumee technology with tcpO2, we look forward"

TcPO2 (transcutaneous oxygen pressure) is a noninvasive measurement of how much oxygen is reaching tissues just beneath the skin, obtained by placing a warmed sensor on the skin surface. For investors, it matters because TcPO2 is used to evaluate wound healing, peripheral circulation and the effectiveness of therapies or monitoring devices; stronger clinical utility or better measurement accuracy can drive demand, reimbursement and regulatory value—similar to checking soil moisture to predict plant health.

pilot clinical study medical

"Profusa’s US-based pilot clinical study on Wednesday, January 28th"

A pilot clinical study is a small, early trial that tests whether a new medical treatment or procedure is feasible, safe and worth studying further, like a prototype test drive before mass production. For investors, pilot results provide the first real-data signals about whether a therapy shows promise, what risks or side effects appear, and whether larger, more expensive trials are likely — information that can meaningfully change a company’s development plan and valuation.

AI-generated analysis. Not financial advice.

Study conducted at US sites evaluates Lumee^TM in peripheral artery disease (PAD) patients

BERKELEY, Calif, Dec. 11, 2025 (GLOBE NEWSWIRE) -- Profusa, Inc. (“Profusa” or the “Company”) (Nasdaq: PFSA), a commercial stage digital health company pioneering a next-generation technology platform enabling the continuous monitoring of an individual’s biochemistry, announces the acceptance of their abstract at the upcoming Leipzig Interventional Course (LINC) 2026, being held January 27-30, 2026, in Leipzig, Germany. The presentation will discuss additional insights into tissue oxygen monitoring of PAD patients from Profusa’s US-based pilot clinical study on Wednesday, January 28^th, 2026, 9:45am CET at the Trade Fair Leipzig, Hall 2.

“Our proprietary Lumee oxygen tissue monitoring technology enables continuous, real-time measurement of tissue oxygen directly within the body, intended for use both in the clinic and at home,” said Ben Hwang, Ph.D., Profusa’s Chairman and CEO. “With positive feedback from our U.S.-based clinical study evaluating our pioneering Lumee technology with tcpO₂, we look forward to sharing additional clinical results and continued discussion with providers and researchers at this preeminent European conference.”

About Profusa
Based in Berkeley, Calif., Profusa is a commercial stage digital health company led by visionary scientific founders, an experienced management team and a world-class board of directors in the development of a new generation of tissue-integrated sensors to detect and continuously transmit actionable, medical-grade data for personal and medical use. With its long-lasting, injectable and affordable biosensors and its intelligent data platform, Profusa aims to provide people with a personalized biochemical signature rooted in data that clinicians can trust and rely on.

“LUMEE”, “PROFUSA” and the PROFUSA logo are registered trademarks of Profusa Inc. in the United States, Canada, European Union, China, Japan, South Korea and Australia.

For more information, visit https://profusa.com.

Special Note Regarding Forward-Looking Statements
Certain statements in this press release (this “Press Release”) may be considered “forward-looking statements” within the meaning of the “safe harbor” provisions of the United States Private Securities Litigation Reform Act of 1995. Forward-looking statements generally relate to future events or future financial or operating performance of Profusa. In some cases, you can identify forward-looking statements by terminology such as “anticipate,” “believe,” “continue,” “could,” “estimate,” “expect,” “forecast,” “future,” “intend,” “may,” “might,” “plan,” “possible,” “potential,” “predict,” “project,” “propose,” “seek,” “should,” “strive,” “will,” or “would” or the negatives of these terms or variations of them or similar terminology. Such forward-looking statements are subject to risks, uncertainties, and other factors which may be beyond the control of Profusa and could cause actual results to differ materially from those expressed or implied by such forward-looking statements. These forward-looking statements are based upon estimates and assumptions that, while considered reasonable by Profusa and its management are inherently uncertain. Profusa cautions you that these statements are based on a combination of facts and factors currently known and projections of the future, which are inherently uncertain. There are risks and uncertainties described in the definitive proxy/final prospectus relating to the business combination, which has been filed with the SEC, and in other documents filed by Profusa from time to time with the SEC. These filings may identify and address other important risks and uncertainties that could cause actual events and results to differ materially from those contained in the forward-looking statements. Profusa cannot assure you that the forward-looking statements in this communication will prove to be accurate.

Contacts
Investor and Media Contacts
email: info@coreir.com
phone: 1 (212) 655-0924

FAQ

What will Profusa (PFSA) present at LINC 2026 on January 28, 2026?

Profusa will present additional clinical insights from its US pilot study evaluating the Lumee tissue oxygen monitoring technology in PAD patients, including comparisons with tcpO2.

When and where is Profusa's PFSA presentation at Leipzig Interventional Course (LINC) 2026?

The presentation is scheduled for January 28, 2026 at 9:45am CET at Trade Fair Leipzig, Hall 2.

What patient group was studied in Profusa's US pilot clinical study for Lumee (PFSA)?

The US pilot clinical study evaluated Lumee in patients with peripheral artery disease (PAD).

What measurement does Profusa's Lumee technology provide according to the announcement?

Lumee provides continuous, real-time tissue oxygen monitoring measured directly within the body for clinic and at-home use.

Does the Profusa announcement state any numerical study results or clinical endpoints for PFSA?

No; the announcement describes additional clinical insights and positive feedback but does not disclose numerical results or specific endpoints.